NCT06770959

Brief Summary

The aim of this work is to identify different pattern of Gastrointestinal and Hepatic symptoms and its Frequency among patients with Multiple Sclerosis

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
7mo left

Started Jan 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress70%
Jan 2025Dec 2026

First Submitted

Initial submission to the registry

December 27, 2024

Completed
5 days until next milestone

Study Start

First participant enrolled

January 1, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 13, 2025

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

January 13, 2025

Status Verified

January 1, 2025

Enrollment Period

1.9 years

First QC Date

December 27, 2024

Last Update Submit

January 7, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Detection of Prevalence of git and hepatic manifestation in people with MS and its relations to MS treatment

    24 month

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

both genders people on remission any age

You may qualify if:

  • both sex 2- All patients diagnosed MS ( in recovery on DMT) according to the 2017-McDonalds criteria.
  • Pt with MS suffer from git and hepatic symptoms not explained by known cause as Hepatitis virus،metabolic disorders as Wilson . hemochromatosis,etc Drug induced , Alcohol , Git symptoms as dysphagia, vomiting,reflux
  • An informed consent will be obtained from all the patients, the study will be approved by ethical committee in faculty of Medicine Assiut University

You may not qualify if:

  • \_ Presence of other disorder or on medications that may affect the neurological or GIT disorders.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Levinthal DJ, Rahman A, Nusrat S, O'Leary M, Heyman R, Bielefeldt K. Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int. 2013;2013:319201. doi: 10.1155/2013/319201. Epub 2013 Sep 17.

    PMID: 24163768BACKGROUND

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System Diseases

Central Study Contacts

Nayera Mohamed Refaat, master degree

CONTACT

Shady Mohamed Safwat, doctor

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

December 27, 2024

First Posted

January 13, 2025

Study Start

January 1, 2025

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

January 13, 2025

Record last verified: 2025-01